Cingulate Inc. Selling, General and Administrative Expense
Cingulate Inc. (CING) reported Selling, General and Administrative Expense of $3.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-13
- Cingulate Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $3.93M, a 101.54% increase year-over-year.
- Cingulate Inc. selling, general and administrative expense for the quarter ending 2025-06-30 was $1.95M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month |
|---|---|---|
| 2026-06-30 | $3.93M 10-Q · filed 2026-08-13 | $9.67M 10-Q · filed 2026-08-13 |
| 2025-06-30 | $1.95M 10-Q · filed 2026-08-13 | $3.43M 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |